Long-term human or animal studies on adalimumab have not been conducted, leaving the toxicity profile mostly unknown. It has not been demonstrated to be mutagenic in vitro or in vivo studies.

The FDA categorizes adalimumab as a pregnancy category B drug. There is no conclusive published evidence of poor pregnancy outcomes or specific patterns of defects in infants exposed prenatally to adalimumab.